Skip to main content
DMAC logo

DMAC

DiaMedica Therapeutics Inc.

$8.25

2.91%

Trade Ideas Performance

Latest Closed Trade Idea

$8.25

2.91%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

2

Social

3

About

Events of DiaMedica Therapeutics Inc. (DMAC)

Over the past six months (approximately May-November 2026), DiaMedica's stock was impacted by earnings reports, including Q2 2026 results matching forecasts and the upcoming Q3 2026 release. Significant clinical trial progress included the enrollment of the 200th patient in the ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial, reaching a 75% enrollment milestone, and positive interim Phase 2 results for preeclampsia showing statistically significant blood pressure reductions, with an interim efficacy analysis for ReMEDy2 anticipated in Q1 2027. Analyst ratings varied, with a consensus 'Moderate Buy' and price targets ranging from $12.00 to $15.50, while the stock reached a new 52-week high.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)